Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2014 Feb;7(1):5-7.
doi: 10.1161/CIRCGENETICS.114.000507.

Vascular Ehlers-Danlos syndrome: exploring the role of inflammation in arterial disease

Dianna M Milewicz  1 , Amy J Reid, Alana C Cecchi
Affiliations
Editorial

Vascular Ehlers-Danlos syndrome: exploring the role of inflammation in arterial disease

Dianna M Milewicz et al. Circ Cardiovasc Genet. 2014 Feb.
No abstract available

Keywords: C-reactive protein; Editorials; Ehlers-Danlos syndrome, vascular type; collagen type III.

PubMed Disclaimer

Comment on

References

    1. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers Danlos syndrome type IV, the vascular type. N Engl J Med. 2000;342:673–680. - PubMed
    1. Chu LC, Johnson PT, Dietz HC, Brooke BS, Arnaoutakis GJ, Black JH, III, et al. Vascular complications of Ehlers-Danlos syndrome: CT findings. AJR Am J Roentgenol. 2012;198:482–487. - PubMed
    1. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers Danlos syndrome type IV, the vascular type. N Engl J Med. 2000;342:673–680. see comments. - PubMed
    1. Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ. Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers Danlos Support Group (UK) Am J Med Genet. 1998;77:31–37. - PubMed
    1. Ong KT, Perdu J, De BJ, Bozec E, Collignon P, Emmerich J, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010;376:1476–1484. - PubMed

Substances